Management of patients with metastatic cancer of unknown primary

Current Problems in Surgery

Volumn 42, Issue 1, 2005, Pages 12-66

  Ghosh, Dimal C ^a  

^a State University Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTHRACYCLINE; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALRETININ; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYTOKERATIN; DOCETAXEL; DOXORUBICIN; EOSIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; HEMATOXYLIN; MITOMYCIN C; NERVE CELL ADHESION MOLECULE; PACLITAXEL; PLATINUM; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNINDEXED DRUG; UROPLAKIN; VILLIN;

ADENOCARCINOMA; AXILLARY LYMPH NODE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; ENDOCRINE TUMOR; ENDOSCOPY; EWING SARCOMA; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; MAMMOGRAPHY; MELANOMA; MESOTHELIOMA; METASTASIS POTENTIAL; MICROSCOPY; MOLECULAR GENETICS; NAUSEA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE ADENOCARCINOMA; REVIEW; RHABDOMYOSARCOMA; SMALL CELL CARCINOMA; SMALL CELL SARCOMA; SOFT TISSUE TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; VOMITING;

EID: 12744278493     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2004.10.002     Document Type: Note

References (147)

1. A. Jemal T. Murray A. Samuels A. Ghafoor E. Ward M.J. Thun Cancer statistics, 2003 CA Cancer J Clin 53 2003 5-26
2. J.L. Abbruzzese M.N. Raber Unknown primary In: M.F. Abeloff J.O. Armitage A.S. Lichter, editors Clinical Oncology 1995 Churchill Livingstone Inc New York 1833-1845
3. R.T. Greenlee T. Murray S. Bolden et al. Cancer statistics, 2000 CA Cancer J Clin 50 2000 7-33
4. M.S. Didolker N. Fanous E.G. Elisa et al. Metastatic carcinomas from occult primary tumors: A study of 254 patients Ann Surg 186 1997 625-630
5. H. Komuro S. Imaizumi A. Hirata et al. Congenital mediastinal dumbbell neuroblastoma with spontaneous regression of liver metastases Pediatr Surg Int 12 1998 86-88
6. J.L. Abbruzzese R. Lenzi M.N. Raber et al. The biology of unknown primary tumors Semin Oncol 20 1993 238-243
7. F.A. Greco J.D. Hainsworth Chapter 48: Cancer of unknown primary site In: V.T. Devita S. Hellman S. Rosenberg, editors Cancer: Principles and Practice of Oncology 2001 Lippincott Williams & Wilkins Philadelphia 2537-2560
8. J.D. Hainsworth F.A. Greco Treatment of patients with cancer of an unknown primary site N Engl J Med 329 1993 257-263
9. N. Pavlidis Cancer of unknown primary: Biological and clinical characteristics Ann Oncol 14 Suppl 3 2003 iii11-iii18
10. Cancer Facts and Figures 2003 American Cancer Society
11. E. Briasoulis M. Tsokos G. Fountzilas et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications: A Hellenic Co-Operative Oncology Group study Anticancer Res 18 1998 1907-1914
12. M. Bar-Eli J.L. Abbruzzese D. Lee-Jackson P. Frost p53 gene mutation spectrum in human unknown primary tumors Anticancer Res 13 1993 1619-1623
13. N. Pavlidis E. Briassoulis M. Bai G. Fountzilas N. Agnantis Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin Anticancer Res 15 1995 2563-2567
14. P.R. Karsell P.F. Sheedy 2nd M.J. O'Connell Computed tomography in search of cancer of unknown origin Jama 248 1982 340-343
15. J.H. McMillan E. Levine R.H. Stephens Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site: A retrospective study Radiology 143 1982 143-146
16. H.Y. Al-Idrissi Combined 5-fluorouracil, adriamycin and mitomycin-C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site J Intern Med Res 18 1990 425-429
17. F.A. Greco J.D. Hainsworth Cancer of unknown primary site In: V.T. Davita S. Hellman S.A. Rosenberg et al., editors Cancer: Principles and Practice of Oncology 1997 Lippincott-Raven Philadelphia 2423-2443
18. J.H. McMillan E. Levine R.H. Stephens Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site Radiology 143 1982 143-146
19. J.F. Stewart M.H. Tattersall R.L. et al. Woods Unknown primary adenocarcinoma: Incidence of over investigation and natural history BMJ 1 1979 1530-1533
20. R.O. Johnson R. Castro F.J. Ansfield Response of primary unknown cancers to treatments with 5-fluorouracil Cancer Chemother Rep 38 1964 63
21. F.A. Greco J.D. Hainsworth The evolving role of paclitaxel for patients with carcinoma of unknown primary site Semin Oncol 26 1999 129-133
22. B.C. Lembersky L.C. Thomas Metastases of unknown primary site Med Clin North Am 80 1996 153-171
23. L.S. Carlson G.H. Fletcher M.J. Oswald Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary Int J Radiat Oncol Biol Phys 12 1986 2101-2110
24. R.A. Shildt P.S. Kennedy T.T. Chen et al. Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group study Cancer Treat Rep 67 1983 77-79
25. J.D. Hainsworth E.P. Wright G.F. Gray Jr et al. Poorly differentiated carcinoma of unknown primary site: Correlation of light microscopic findings with response to cisplatin-based combination chemotherapy J Clin Oncol 5 1987 1275-1280
26. J.D. Hainsworth D.H. Johnson F.A. Greco Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12 year experience J Clin Oncol 10 1992 912-922
27. J.L. Abbruzzese M.C. Abbruzzese K.R. Hess et al. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients J Clin Oncol 12 1994 1272-1280
28. J.D. Hainsworth E.P. Wright D.H. Johnson et al. Poorly differentiated carcinoma of unknown primary site: Clinical usefulness of immunoperoxide staining J Clin Oncol 9 1991 1931-1938
29. S.B. Lele M.S. Piver J. Matharu et al. Peritoneal papillary carcinoma Gynecol Oncol 31 1988 315-320
30. S.G. Orel S.P. Weinstein M.D. Schnall et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy Radiology 212 1999 543-549
31. S.K. Bhatia T.J. Saclarides T.R. Witt et al. Hormone receptor studies in axillary metastases from occult breast cancer Cancer 59 1987 1170-1172
32. G.N. Hortobagyi A.U. Buzdar Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy CA Cancer J Clin 45 1995 199-226
33. J. Patel T. Nemoto D. Rosner et al. Axillary lymph node metastasis from an occult breast cancer Cancer 47 1981 2923-2927
34. R. Ashikari P.P. Rosen J.A. et al. Urban Breast cancer presenting as an axillary mass Ann Surg 183 1976 415-417
35. P.L. Baron M.P. Moore D.W. Kinne et al. Occult breast cancer presenting with axillary metastases; updated management Arch Surg 125 1990 210-214
36. N. Ellerbrock F. Holmes E. Singletary et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin Cancer 66 1990 1461-1467
37. B. Fisher S. Anderson C.K. Redmond et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med 333 1995 1456-1461
38. I.M. Obdeijn E.M. Brouwers-Kuyper M.M. Tilanus-Linthorst T. Wiggers M. Oudkerk MR imagining-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast AJR Am J Roentgenol. 174 2000 1079-1084
39. F.R. Margolin Needle localization guided excisional biopsy for mammographically identified nonpalpable breast lesions Pathology (Phila) 1 1992 1-10
40. A.J. Leibma M.B. Kossoff Mammography in women with axillary lymphadenopathy and normal breast on physical examination: Value in detecting occult breast carcinoma AJR Am J Roentgenol 159 1992 493-495
41. P. Mantaka R.P. Baum A. Hertel S. Adams A. Niessen S. Sengupta G. Hor PET with 2- [F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): Influence on patient's diagnostic and therapeutic management Cancer Biother Radiopharm 18 2003 47-58
42. G. Regelink J. Brouwer R. de Bree J. Pruim B.F. van der Laan W. Vaalburg O.S. Hoekstra E.F. Comans A. Vissink C.R. Leemans J.L. Roodenburg Detection of unknown primary tumors and distant metastases in patients with cervical metastases: Value of FEG-PET versus conventional modalities Eur J Nucl Med Mol Imaging 29 2002 1024-1030
43. J.J. Peterson M.J. Kransdorf M.I. O'Connor Diagnosis of occult bone metastased: Positron emission tomography (review) Clin Orthop Oct 5 Suppl 2003 S120-S128
44. C. Volpe R.J. Doerr Somatostreceptor scintigraphy and endoscopic ultrasonography for occult carcinoid tumor Arch Surg 134 1999 575-576
45. S.J. Harwood J Nucl Med 44 2003 27P
46. S.G. Orel S.P. Weinstein M.D. Schnall et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy Radiology 212 1999 543-549
47. Occult Primary. Vol. 2003 2003 National Comprehensive Cancer Network, American Cancer Society
48. R. Bugat A. Bataillard T. Lesimple et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002) Br J Cancer 89 Suppl 1 2003 S59-S66
49. R. Katoh A. Kawaoi E. Miyagi X. Li K. Suzuki Y. Nakamura K. Kakudo Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization Mod Pathol 13 2000 570-576
50. P.A. Bejarano Y.E. Nikiforov E.S. Swenson P.W. Biddinger Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms Appl Immunohistochem Mol Morphol 8 2000 189-194
51. J.F. Silverman Metastatic malignancies of unknown origin Pathol Case Rev 6 2001 4135-4136
52. S. Raab Cost analysis for pathologic evaluation of metastatic carcinoma of unknown origin Pathol Case Rev 6 2001 4173-4177
53. B.C. Lembersky Metastatic malignancies of unknown primary: The medical oncologist's point of view Pathol Case Rev 6 2001 4178-4
54. L.A. Cerilli M.R. Wick Metastatic malignancies of unknown origin: A histologic and cytologic approach to diagnosis Pathol Case Rev 6 2001 4137-4145
55. S.P. Hammar Metastatic adenocarcinoma of unknown primary origin Hum Pathol 29 1998 1393-1402
56. D.J. Dabbs J.F. Silverman Immunohistochemical work up of metastatic carcinoma of unknown primary Pathol Case Rev 6 2001 4146-4153
57. J. Sidhu R.L. Sanchez Prostatic acid phosphatase in strumal carcinoids of the ovary: An immunohistochemical study Cancer 72 1993 1673-1678
58. M. Varma M. Morgan B. Jasani P. Tamboli M.B. Amin Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology Am J Clin Pathol 118 2002 202-207
59. D. Tan Q. Li G. Deeb et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study Hum Pathol 34 2003 597-604
60. N. Nakamura E. Miyagi S. Murata A. Kawaoi R. Katoh Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues Mod Pathol 15 2002 1058-1067
61. M. Wu B. Wang J. Gil E. Sabo L. Miller L. Gan D.E. Burstein p63 and TTF-1 immunostaining: A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung Am J Clin Pathol 119 2003 696-702
62. J. Zamecnik R. Kodet Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: A study of 109 cases Virchows Arch 440 2002 353-361
63. M.R. Wick T.J. Lillemoe G.T. Copland P.E. Swanson J.C. Manivel D.T. Kiang Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin Hum Pathol 20 1989 281-287
64. O. Kaufmann J. Volmerig M. Dietel Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas Am J Clin Pathol 113 2000 683-687
65. P. Chu E. Wu L.M. Weiss Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases Mod Pathol 13 2000 962-972
66. J. Tan G. Sidhu M.A. Greco H. Ballard R. Wieczorek Villin, cytokeratin 7, and cytokeratin 20 expression in pulmonary adenocarcinoma with ultrastructural evidence of microvilli with rootlets Hum Pathol 29 1998 390-396
67. S. Hammarstrom The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 1999 67-81
68. C.E. Bacchi A.M. Gown Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue Lab Invest 64 1991 418-424
69. R. Moll S. Robine B. Dudouet D. Louvard Villin: A cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas Virchows Arch B Cell Pathol Incl Mol Pathol 54 1987 155-169
70. R.W. Werling H. Yaziji C.E. Bacchi A.M. Gown CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas Am J Surg Pathol 27 2003 303-310
71. N.S. Goldstein D. Bassi A. Uzieblo WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms Am J Clin Pathol 116 2001 246-252
72. N.S. Goldstein A. Uzieblo WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas Am J Clin Pathol 117 2002 541-545
73. Y. Oji S. Miyoshi H. Maeda et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers Int J Cancer 100 2002 297-303
74. Y. Oji H. Yamamoto M. Nomura et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma Cancer Sci 94 2003 712-717
75. S. Rangdaeng L.D. Truong Comparative immunohistochemical staining for desmin and muscle-specific actin: A study of 576 cases Am J Clin Pathol 96 1991 32-45
76. S. Kumar E. Perlman C.A. Harris M. Raffeld M. Tsokos Myogenin is a specific marker for rhabdomyosarcoma: An immunohistochemical study in paraffin-embedded tissues Mod Pathol 13 2000 988-993
77. R.E. Jimenez A.L. Folpe R.L. Lapham J.Y. Ro P.A. O'Shea S.W. Weiss M.B. Amin Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: A clinicopathologic and immunohistochemical analysis of 11 cases Am J Surg Pathol 26 2002 320-327
78. A.L. Folpe C.E. Hill D.M. Parham P.A. O'Shea S.W. Weiss Immunohistochemical detection of FLI-1 protein expression: A study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor Am J Surg Pathol 24 2000 1657-1662
79. T. Hasegawa T. Hirose A.G. Ayala S. Ito U. Tomaru Y. Matsuno T. Shimoda S. Hirohashi Adult neuroblastoma of the retroperitoneum and abdomen: clinicopathologic distinction from primitive neuroectodermal tumor Am J Surg Pathol 25 2001 918-924
80. S.N. Leech A.J. Kolar P.D. Barrett S.A. Sinclair N. Leonard Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1 J Clin Pathol 54 2001 727-729
81. A.L. Byrd-Gloster A. Khoor L.F. Glass J.L. Messina J.A. Whitsett S.K. Livingston P.T. Cagle Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor Hum Pathol 31 2000 58-62
82. S.N. Agoff L.W. Lamps A.T. Philip M.B. Amin R.A. Schmidt L.D. True A.L. Folpe Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors Mod Pathol 13 2000 238-242
83. P.J. Zhang J.R. Goldblum B.R. Pawel C. Fisher T.L. Pasha F.G. Barr Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product Mod Pathol 16 2003 229-235
84. D.A. Hill J.D. Pfeifer E.F. Marley L.P. Dehner P.A. Humphrey X. Zhu P.E. Swanson WT1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor: An immunohistochemical and molecular diagnostic study Am J Clin Pathol 114 2000 345-353
85. M.V. de Silva A.D. McMahon L. Paterson R. Reid Identification of poorly differentiated synovial sarcoma: A comparison of clinicopathological and cytogenetic features with those of typical synovial sarcoma Histopathology 43 2003 220-230
86. S. Suster C.A. Moran H. Dominguez-Malagon P. Quevedo-Blanco Germ cell tumors of the mediastinum and testis: A comparative immunohistochemical study of 120 cases Hum Pathol 29 1998 737-742
87. J.D. Hainsworth D.H. Johnson F.A. Greco Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience J Clin Oncol 10 1992 912-922
88. K. Blessing D.S. Sanders J.J. Grant Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants Histopathology 32 1998 139-146
89. M. Miettinen M. Fernandez K. Franssila Z. Gatalica J. Lasota M. Sarlomo-Rikala Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: Comparison with four other melanoma markers Am J Surg Pathol 25 2001 205-211
90. F.M. O'Reilly D.J. Brat B.E. McAlpine H.E. Grossniklaus A.L. Folpe J.L. Arbiser Microphthalmia transcription factor immunohistochemistry: A useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms J Am Acad Dermatol 45 2001 414-419
91. J. Iwata C.D. Fletcher Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: A systematic study of 100 cases Pathol Int 50 2000 7-14
92. A. Taki Y. Nakatani K. Misugi M. Yao Y. Nagashima Chromophobe renal cell carcinoma: An immunohistochemical study of 21 Japanese cases Mod Pathol 12 1999 310-317
93. A. Kondi-Pafitis E. Kairi K.I. Kontogianni C. Dimopoulou K. Sikiotis V. Smyrniotis Immunopathological study of mesonephric lesions of cervix uteri and vagina Eur J Gynaecol Oncol 24 2003 154-156
94. R.B. Rezende C.B. Drachenberg D. Kumar R. Blanchaert R.A. Ord O.B. Ioffe J.C. Papadimitriou Differential diagnosis between monomorphic clear cell adenocarcinoma of salivary glands and renal (clear) cell carcinoma Am J Surg Pathol 23 1999 1532-1538
95. H.D. Tazelaar K.P. Batts J.R. Srigley Primary extrapulmonary sugar tumor (PEST): A report of four cases Mod Pathol 14 2001 615-622
96. Z. Fan M. van de Rijn K. Montgomery R.V. Rouse Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections Mod Pathol 16 2003 137-144
97. C. Morrison W. Marsh Jr W.L. Frankel A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver Mod Pathol 15 2002 1279-1287
98. S. Kakar T. Muir L.M. Murphy R.V. Lloyd L.J. Burgart Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma Am J Clin Pathol 119 2003 361-366
99. S.K. Lau S. Prakash S.A. Geller R. Alsabeh Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma Hum Pathol 33 2002 1175-1181
100. J. Clover J. Oates C. Edwards Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma Histopathology 31 1997 140-143
101. N.G. Ordonez Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma Am J Surg Pathol 22 1998 1215-1221
102. C. Doglioni A.P. Tos L. Laurino P. Iuzzolino C. Chiarelli M.R. Celio G. Viale Calretinin: A novel immunocytochemical marker for mesothelioma Am J Surg Pathol 20 1996 1037-1046
103. N.G. Ordonez Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma Am J Surg Pathol 24 2000 598-606
104. M.R. Foster J.E. Johnson S.J. Olson D.C. Allred Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas Arch Pathol Lab Med 125 2001 1316-1320
105. N.G. Ordonez Value of mesothelin immunostaining in the diagnosis of mesothelioma Mod Pathol 16 2003 192-197
106. N.G. Ordonez Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma Hum Pathol 34 2003 749-755
107. J. Patel T. Nemoto D. Rosner T.L. Dao J.W. Pickren Axillary lymph node metastasis from an occult breast cancer Cancer 47 1981 2923-2927
108. M.M. Tilanus-Linthorst A.I. Obdeijn M. Bontenbal M. Oudkerk MRI in patients with axillary metastases of occult breast carcinoma Breast Cancer Res Treat 44 1997 179-182
109. C.M. Strnad W.W. Grosh J. Baxter L.S. Burnett H.W. Jones 3rd F.A. Greco J.D. Hainsworth Peritoneal carcinomatosis of unknown primary site in women: A distinctive subset of adenocarcinoma Ann Intern Med 111 1989 213-217
110. N.G. Ordonez B. Mackay Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era Hum Pathol 29 1998 1403-1411
111. M. Sobrinho-Simoes J.V. Johannessen V.E. Gould The diagnostic significance of intracytoplasmic lumina in metastatic neoplasms Ultrastruct Pathol 2 1981 327-335
112. G.L. Carlso Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary Int J Radiat Oncol Biol Phys 12 1986 2101-2110
113. A.J. Leibman M.B. Kossoff Mammography in women with axillary lymphadenopathy and normal breasts on physical examination: Value in detecting occult breast carcinoma AJR Am J Roentgenol 159 1992 493-495
114. C. Nieder V. Gregoire K.K. Ang Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 50 2001 727-733
115. C. Grau L.V. Johansen J. Jakobsen P. Geertsen E. Andersen B.B. Jensen Cervical lymph node metastases from unknown primary tumours: Results from a national survey by the Danish Society for Head and Neck Oncology Radiother Oncol 55 2000 121-129
116. E.S. Nussbaum H.R. Djalilian K.H. Cho W.A. Hall Brain metastases: histology, multiplicity, surgery, and survival Cancer 78 1996 1781-1788
117. S. Bartelt J. Lutterbach Brain metastases in patients with cancer of unknown primary J Neurooncol 64 2003 249-253
118. T. Le Chevalier F.P. Smith P. Caille J.P. Constans J.G. Rouesse Sites of primary malignancies in patients presenting with cerebral metastases: A review of 120 cases Cancer 56 1985 880-882
119. L.N. Nguyen M.H. Maor M.J. Oswald Brain metastases as the only manifestation of an undetected primary tumor Cancer 83 1998 2181-2184
120. R.A. Patchell P.A. Tibbs J.W. Walsh et al. A randomized trial of surgery in the treatment of single metastases to the brain N Engl J Med 322 1990 494-500
121. E.M. Noordijk C.J. Vecht H. Haaxma-Reiche et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age Int J Radiat Oncol Biol Phys 29 1994 711-717
122. D.L. Bartlett Chapter 49: Peritoneal Carcinomatosis In: V.T. Devita S. Hellman S. Rosenberg, editors Cancer: Principles and Practice of Oncology 2001 Lipincott Williams & Wilkins Philadelphia 2561-2574
123. S. Wilailak V. Linasmita S. Srivannaboon Malignant ascites in female patients: A seven-year review J Med Assoc Thai 82 1999 15-19
124. F.M. Muggia J. Baranda Management of peritoneal carcinomatosis of unknown primary tumor site Semin Oncol 20 1993 268-272
125. J.L. Rutter S. Wacholder A. Chetrit et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study J Natl Cancer Inst 95 2003 1072-1078
126. A.W. Kennedy M. Markman K.D. et al. Webster Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum Gynecol Oncol 71 1998 288-290
127. N. Pavlidis E. Briasoulis J. Hainsworth F.A. Greco Diagnostic and therapeutic management of cancer of an unknown primary Eur J Cancer 39 2003 1990-2005
128. J.D. Hainsworth D.H. Johnson F.A. Greco Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity Ann Intern Med 109 1988 364-371
129. C.G. Moertel L.K. Kvols M.J. O'Connell J. Rubin Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 1991 227-232
130. F.A. Greco W.K. Vaughn J.D. Hainsworth Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome Ann Intern Med 104 1986 547-553
131. J.R. Sporn B.R. Greenberg Empirical chemotherapy for adenocarcinoma of unknown primary tumor site Semin Oncol 20 1993 261-267
132. F.A. Greco H.A. Burris III J.B. Erland et al. Carcinoma of unknown primary site Cancer 89 2000 2655-2660
133. F.A. Greco H.A. Burris III S. Litchy et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study J Clin Oncol 20 2002 1651-1656
134. C.I. Falkson G.L. Cohen Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin Oncology 55 1998 116-121
135. E. Briasoulis H. Kalofonos D. Bafaloukos et al. Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study J Clin Oncol 18 2000 3101-3107
136. E. Guardiola X. Pivot X. Tchicknavorian et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: A phase II trial Am J Clin Oncol 24 2001 372-375
137. J.E. Dowell A.M. Garrett Y. Shyr D.H. Johnson K.R. Hande A randomized phase II trial in patients with carcinoma of an unknown primary site Cancer 91 2001 592-597
138. A.G. Macdonald M.C. Nicolson L.M. Samuel A.W. Hutcheon F.Y. Ahmed A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site Br J Cancer 86 2002 1238-1242
139. F.A. Greco J.B. Erland L.H. Morrissey et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin Ann Oncol 11 2000 211-215
140. E. Voog Y. Merrouche V. Trillet-Lenoir et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary Am J Clin Oncol 23 2000 614-616
141. F.J. Lofts H. Gogas J.L. Mansi Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam) Ann Oncol 10 1999 1389-1392
142. E. Briasoulis N. Tsavaris G. Fountzilas et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: Hellenic Co-Operative Oncology Group Phase II Study Oncology 55 1998 426-430
143. S. Culine A. Lortholary J.J. Voigt et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) J Clin Oncol 21 2003 3479-3482
144. J.D. Hainsworth J.B. Erland L.A. Kalman M.T. Schreeder F.A. Greco Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide J Clin Oncol 15 1997 2385-2393
145. F.A. Greco J. Gray H.A. Burris 3rd J.B. Erland L.H. Morrissey J.D. Hainsworth Taxane-based chemotherapy for patients with carcinoma of unknown primary site Cancer J 7 2001 203-212
146. F. Levi V.C. Te G. Erler L. Randimbison C. La Vecchia Epidemiology of unknown primary tumours Eur J Cancer 38 2002 1810-1812
147. A.J. van de Wouw M.L. Janssen-Heijnen J.W. Coebergh H.F. Hillen Epidemiology of unknown primary tumours: Incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992 Eur J Cancer 38 2002 409-413